Aevi Genomic initiates Phase I/II trial of AEVI-001 to treat 22q DS

US-based Aevi Genomic Medicine has initiated its Phase I/II clinical trial with the enrolment and dosing of its first patient with AEVI-001 (NFC-1) to treat 22q11.2 deletion syndrome (22q DS) in children.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news